AIMN Multicenter Study: Staging of Lymphomas Using PET/CT

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06179693

Enrollment

Registered

2023-12-22

Start date

2009-10-07

Completion date

2011-02-24

Last updated

2023-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma

Brief summary

In recent years, the introduction of PET/CT tomographs (which have now almost completely replaced tomographs equipped with PET alone), has allowed a significant increase in diagnostic accuracy in the majority of tumors. However, in order to reduce the radiation doses, administering CT images are acquired for patients at a low dose (generally 60mA 120kV) without the use of contrast agents. This prudential attitude, however, makes it essential to carry out diagnostic CT investigations which, at the end of the diagnostic process It leads to an increase in the dose administered for the patient rather than to savings. This study aims to evaluate the possible advantages in diagnostic, economic and quality of life terms of PET/CT performed with diagnostic CT with intravenous contrast medium, with the aim of benefiting the neoplastic patient in the diagnostic process by optimizing (from a temporal and dosimetric point of view ) the diagnostic procedures to which it is subjected. It is expected that the integrated PET/CT procedure can facilitate the process of staging the neoplasm and that this procedure can have a positive impact on the patient's quality of life while also reducing the costs incurred in terms of time and money.

Interventions

DIAGNOSTIC_TESTDiagnostic accuracy

As per standard procedure, patients will undergo FDG PET. Following the PET exam it will be acquired a standard CT with intravenous contrast medium, using the CT tomograph inserted inside the PET one.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Established lymphoma (non-Hodgkin's lymphoma and Hodgkin's disease) being staged; * Performing the PET/CT examination within two weeks of diagnosis and before treatment; * Signing of the Informed Consent.

Exclusion criteria

* patients \<18 years; * Patients who have not signed the Informed Consent; * Execution of previous anti-inflammatory or anti-inflammatory therapies in the 4 weeks preceding the PET exam.

Design outcomes

Primary

Measure	Time frame
PET/CT with contrast medium in a single session to diagnosis of patients with malignant limphoma.	2 years

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026